Title: Antifungal drug shows promise as antitumour agent
Abstract: Clinical researchers in London report exciting antitumour activity by the antifungal drug trichostatin A (Clin Cancer Res 2001; 7: 971–76). The data reveal potent dose-dependent activity, both in vitro and in a rat mammary carcinoma model. Trichostatin A acts by inhibiting the function of the cellular enzyme histone deacetylase (HDAC). This enzyme is involved in modulating the topology of chromatin, causing it to become transcriptionally silent; inhibition of HDAC activity causes transcriptional activation of some genes. Previous in vitro studies showed that trichostatin A was able to cause cell-cycle arrest, to induce differentiation, and to reverse transformed phenotypes of cultured cells. The new study evaluated the efficacy of the drug as a potential new therapy for breast cancer.
Publication Year: 2001
Publication Date: 2001-06-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot